Artelo Biosciences Links FABP5 Inhibition to Linoleic Acid Pathway Across Multiple Diseases — Artelo Biosciences, Inc.

Event summary

Artelo Biosciences presented multi-omics data at ICRS 2026 showing ART26.12, its lead FABP5 inhibitor, consistently modulates linoleic acid metabolism across disease models.
The findings align with independent research from Cornell University published in Science (2025), identifying the linoleic acid-FABP5 axis as a key driver of cancer growth.
ART26.12 is currently in Phase 1 testing for chemotherapy-induced peripheral neuropathy (CIPN) and has demonstrated a favorable safety profile in human studies.

The big picture

Artelo's findings reinforce the broader industry shift toward lipid-signaling pathways as therapeutic targets. The alignment with Cornell University's research strengthens the scientific credibility of FABP5 inhibition, potentially attracting partners for indications beyond Artelo's current focus areas. The company's ability to translate these insights into clinical and commercial success will be critical in a competitive biopharmaceutical landscape.

What we're watching

Clinical Validation: Whether the linoleic acid pathway findings will accelerate ART26.12's development timeline for CIPN and other indications.
Partnership Potential: The pace at which Artelo can leverage these data to secure pharmaceutical partnerships, given the growing interest in lipid-signaling targets.
Competitive Positioning: How Artelo differentiates its FABP5 inhibitor platform against emerging competitors, particularly in oncology and pain management.